Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.85) by 23.53 percent. This is a 96.48 percent increase over losses of $(29.86) per share from the same period last year. The company reported quarterly sales of $1.028 million which beat the analyst consensus estimate of $974.000 thousand by 5.54 percent. This is a 2.93 percent decrease over sales of $1.059 million the same period last year.